| Přispěvatelé: |
Ghezzi, A, Moiola, L, Pozzilli, C, BRESCIA MORRA, Vincenzo, Gallo, P, Grimaldi, Lme, Filippi, M., Brescia Morra, V, Filippi, Massimo, Comi, G, the MS Study Group, – Italian Society of Neurology, Rocca, MARIA ASSUNTA |
| Popis: |
Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p |
